Talecris Biotherapeutics has come out with a portable policy for its liquid immune globulin intravenous Gamunex.
In light of the recent shortages of IVIG products, Talecris Biotherapeutics has come out with a portable policy for its liquid immune globulin intravenous Gamunex. The Research Triangle Park, N.C., firm said that several delivery options are available to patients and physicians that minimize treatment disruptions. Exact details of the portability process vary from customer to customer. Certain aspects of the new policy will be administered by a third party under contract with Talecris. Talecris will also continue to rely on four distributors-ASD Healthcare, Blood Diagnostics Inc., Cardinal Specialty, and FFF Enterprises. Talecris’ new portability policy also applies to the company’s albumin products.